替罗非班在进展性脑梗死中的应用  

Application of Tirofiban in Progressive Cerebral Infarction

作　　者：胡斌彬 罗成宏 陆伟恒 HU Bin-bin;LUO Cheng-hong;LV Wei-heng(Dongguan Third People's Hospital,Dongguan 523000,China)

机构地区：[1]东莞市第三人民医院,广东东莞523000

出　　处：《中国医药指南》2020年第11期86-87,共2页Guide of China Medicine

摘　　要：目的探究进展性脑梗死应用替罗非班进行治疗的临床效果。方法本次实验对象全部选自本院2018年3月至2019年7月期间收治60例进展性脑梗死患者,按照随机表法分成实验组(n=30)和对照组(n=30),进行常规治疗的为对照组,在对照组基础上进行替罗非班治疗的为实验组,对比两种治疗方案对患者NIHSS评分、治疗有效率以及不良反应的影响。结果在治疗总有效率上,实验组和对照组相比(93.33%vs 73.33%),差异有统计学意义(P<0.05)。在用药不良反应发生率上,实验组和对照组相比(6.67%vs 10.00%),差异无统计学意义(P>0.05)。两组患者治疗前的NIHSS评分对比,差异无统计学意义(P>0.05),治疗后相比差异有统计学意义(P<0.05)。结论进展性脑梗死应用替罗非班开展治疗,能够有效缓解神经功能缺损情况,减少用药不良反应的同时提升临床治疗疗效。Objective To explore the clinical effect of tirofiban in the treatment of progressive cerebral infarction.Methods 60 patients with progressive cerebral infarction were selected from our hospital from March 2018 to July 2019.They were randomly divided into experimental group(n=30)and control group(n=30).The control group received routine treatment,and the experimental group received tirofiban treatment on the basis of the control group.The effect of the regimen on patients'NIHSSscore,treatment efficiency and side effects.Results In the total effective rate of treatment,there was significant difference between the experimental group and the control group(93.33%vs 73.33%)(P<0.05).There was no significant difference in the incidence of side effects between the experimental group and the control group(6.67%vs 10.00%)(P>0.05).There was no significant difference in NIHSS score between the two groups before treatment(P>0.05),but there was significant difference after treatment(P<0.05).Conclusion Tirofiban can effectively alleviate the neurological deficit,reduce the side effects of drugs and improve the clinical efficacy of treatment for progressive cerebral infarction.

关 键 词：替罗非班 在进展性脑梗死 NIHSS评分 

分 类 号：R743.3[医药卫生—神经病学与精神病学]